Degrome Therapeutics

Degrome Therapeutics, Inc. is specialized in discovery and development of small molecule degraders of neurodegenerative disease-causing proteins as the first-in-class drugs. The company was founded by Drs. Anita Bellail and Chunhai Hao in 2023 in Indiana after they identified hit compounds as Alzheimer Precursor Protein (APP) degrader.